		1																						
Work packages						First	-												nd year					
	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
WP1 - Project coordination																								
1.1 - Consortium agreement																								
1.2 - Periodic project																								
1.3 - Periodic project financial reports																								
1.4 - Final Report																								
WP2 - Establishment of well-characterised bio-repository																								
2.1 - Development of SOPs for the biorepositroy																								
2.2 - Training off staffs on biobanking principles and standard procedures																								
2.3 - Monitoring and evaluation of GCP during specimen processing and storage																								
2.4 - Supervision of specimen storage and usage for project activties																								
WP3 - Molecular testing																								
3.1 - Technology transfer 3.2 - Concordance among POC and other molecular tests already available for SARS-CoV-2																						-		\square
diagnosis																						-		
3.3 - Testing and quantification of SARS-CoV-2 in clinical samples																								
3.4 - Testing and quantification of SARS-CoV-2 subgenomic RNA in clinical samples																								
3.5 - Sequencing of entire SARS-CoV-2 genomes 3.6 - Viral genetic determinants associated with geographical distribution and the severity of clinical manifestations																								
3.7 - Concordance between Nanopore sequencing and high throughput system																								
3.8 - Sars-Cov-2 burden and replication capacity according with clinical symptoms, SARS-CoV-2 genome variability and SARS-CoV-2 outcome																								
3.9 - Report on scientific publications obtained during the 2 years project																								
WP4 - Serological testing																								
4.1 - Concordance among the serological tests already available for SARS-CoV-2																						П		
4.2 - Timing of seroconversion and neutralization titers																								
4.3 - Kinetics of viral load and antibody development in the course of SARS-CoV-2 infection, and their association with the onset of severe clinical manifestations 4.4 - SARS-CoV-2 genetic variability on the efficiency of performances of immunological																								
diagnostic assays 4.5 - Correlations between neutralizing antibodies and mutations occurring in Spike protein in order to produce a detailed mapping data for neutralizing epitopes.																								
4.6 - Agreement for Technology Transfer between Biotech Companies in China and Italy for serological Rapid and Elisa test in Cameroon and Nigeria																								
WP5 - Capacity development and networking																								
5.1 - SARS-CoV-2 diagnosis reinforcement program																								
5.2 - Measures adopted to enhance recruitment and study visit																								
5.3 - Communication, dissemination and exploitation plan																								
5.4 - Dissemination material																								
WP6 - Ethics and data safety																								
6.1 - First study subject approvals																								
6.2 - CRFs tested and functioning																								
WP7 - Dissemination and communication																								
7.1 - Reinforcement of testing capacity																								
7.2 - Communication to stakeholders - Scientific dissemination																								
7.3 - Dissemination materials with preliminary finding																								
7.4 - Working sessions																								
7.5 - Meeting session with political stakeholders																								
7.6 - Scientific papers																								